MedElevator Войти в исследования
← Поиск публикаций
PLOS digital health · 2026

Screening for patients at risk for cardiac amyloidosis via electronic health records: A multicenter machine learning development and validation study.

СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Spielvogel Clemens P, Kersting David, Haberl David, Autherith Maximilian, Hauptmann Laurenz, Yu Josef, Hennenberg Juliane, Kluge Kilian, Moon Kim, Settelmeier Stephan, Ning Jing, Kumpf Katarina, Köfler Markus, Hofer Felix, Mascherbauer Katharina, Mascherbauer Julia, Kammerlander Andreas, Traub-Weidinger Tatjana, Kasprian Gregor, Rassaf Tienush, Kleesiek Jens, Herrmann Ken, Bartko Philipp, Hengstenberg Christian, Hacker Marcus, Calabretta Raffaella, Nitsche Christian

Аннотация

Timely detection is crucial to improve outcomes in patients with cardiac amyloidosis (CA) by initiation of guideline-directed disease-modifying treatments. Although confirmatory bone scintigraphy is highly accurate for CA detection, identifying at-risk patients for referral remains challenging. This study aimed to develop and validate a machine learning model, Amylo-Detect, using structured multimodal electronic health record (EHR) data to guide referrals for confirmatory scintigraphy and monoclonal protein testing. Consecutive all-comer patients (n = 11,616) referred for bone scintigraphy at the Vienna General Hospital (2010-2023) were retrospectively included. Patients referred before August 2020 formed the development cohort. The remaining patients comprised the internal validation cohort. External validation was performed at the University Hospital Essen (n = 1,521). Amylo-Detect was trained using 50 routinely available parameters to predict CA-suggestive uptake (Perugini grade ≥2) and compared with an existing score and clinical routine. High-grade uptake was present in 388 patients (3.0%). Amylo-Detect demonstrated excellent performance in development (AUC 0.93), independent internal validation (AUC 0.91), and external validation cohort (AUC 0.91), outperforming existing scoring systems and clinical routine. Results were consistent across subgroups, even when crucial predictors were missing. Of the 42/388 (10.8%) patients missed in clinical routine, 12/42 (29%) were additionally detected by Amylo-Detect. The model further conveyed significant prognostic value for mortality and heart failure hospitalization. We present Amylo-Detect, a validated EHR-based tool for CA risk prediction, available as a web app, allowing application and further evaluation. By improving timely detection and referral, Amylo-Detect may help address diagnostic delays, pending prospective evaluation.